NCELNasdaqPharmaceutical PreparationsFiscal year ends December 31

NewcelX Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 29, 2026

$2.63+0.13 (+5.20%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): 1.2
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

Quarter	Reported	Time	Revenue	EPS (GAAP)	EPS (adjusted)
Q4 FY2025 Ended Dec 31, 2025	Apr 30, 2026	Before market open	–	–	–

Press releases

Announcements NewcelX filed with the SEC

Sep 18, 2026, 4:15 PM ET
Interim Consolidated Statements of Profit or Loss and Other Comprehensive Loss
EX-99.1 to Form 6-K
Sep 18, 2026, 4:15 PM ET
NEWCELX LTD.'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE SIX MONTHS ENDED JUNE 30, 2026
EX-99.2 to Form 6-K
Jul 31, 2026, 9:11 AM ET
PRESS RELEASE TITLED: "NEWCELX ANNOUNCES PRICING OF $1.4 MILLION EQUITY FINANCING AT 20% PREMIUM PRICING"
EX-99.1 to Form 6-K
Jul 15, 2026, 9:41 AM ET
PRESS RELEASE TITLED: "NEWCELX GRANTED PATENT IN BRAZIL FOR NCEL-101 IN TYPE 1 DIABETES, EXPANDING GLOBAL IP PORTFOLIO"
EX-99.1 to Form 6-K
Jul 8, 2026, 9:15 AM ET
PRESS RELEASE TITLED: "NEWCELX APPOINTS WORLD-RENOWNED DIABETES CURE-FOCUSED PIONEER, DR. CAMILLO RICORDI, TO SCIENTIFIC ADVISORY BOARD"
EX-99.1 to Form 6-K
Jul 1, 2026, 9:30 AM ET
PRESS RELEASE TITLED: "NEWCELX ANNOUNCES SUCCESSFUL FDA PRE-IND MEETING WITH CLEAR PATH FORWARD FOR NCEL-101 TOWARD STARTING CLINICAL TRIALS FOR TYPE 1 DIABETES"
EX-99.1 to Form 6-K
Jun 15, 2026, 8:42 AM ET
PRESS RELEASE TITLED: "NEWCELX PUBLISHES PEER-REVIEWED STUDY DEMONSTRATING BROAD THERAPEUTIC POTENTIAL OF ITS STEM CELL TECHNOLOGY PLATFORM"
EX-99.1 to Form 6-K
Jun 5, 2026, 4:32 PM ET
NOTICE OF MEETING AND PROXY CARD FOR THE ANNUAL GENERAL SHAREHOLDERS MEETING TO BE HELD ON JUNE 30, 2026.
EX-99.1 to Form 6-K
May 27, 2026, 8:00 AM ET
PRESS RELEASE TITLED: "NEWCELX LTD. SUBMITS PRE-IND PACKAGE TO THE FDA FOR NCEL-101 FOR THE TREATMENT OF TYPE 1 DIABETES"
EX-99.1 to Form 6-K
Apr 30, 2026, 8:18 AM ET
PRESS RELEASE TITLED: "NEWCELX REPORTS FINANCIAL RESULTS FOR 2025 AND PROVIDES SHAREHOLDERS WITH UPDATE ON ACCELERATED DEVELOPMENT OF TYPE 1 DIABETES TREATMENT IN COLLABORATION WITH ELEDON PHARMACEUTICALS IN 2026"
EX-99.1 to Form 6-K
Apr 20, 2026, 7:40 AM ET
PRESS RELEASE TITLED: "NEWCELX UPDATES CORPORATE PRESENTATION TO HIGHLIGHT TYPE 1 DIABETES FLAGSHIP PROGRAM FOLLOWING STRATEGIC COLLABORATION WITH ELEDON PHARMACEUTICALS AHEAD OF SWISS BIOTECH CONFERENCE"
EX-99.1 to Form 6-K
Apr 20, 2026, 7:40 AM ET
Cure Type 1 diabetes We are a clinical stage regenerative medicine company focused on Type 1 Diabetes Cell Therapy using highly enriched stem cell - derived islets as scalable cell replacement therapy 3 3
EX-99.2 to Form 6-K
Apr 1, 2026, 5:03 PM ET
PRESS RELEASE DATED APRIL 1, 2026
EX-99.1 to Form 6-K
Mar 9, 2026, 7:21 AM ET
PRESS RELEASE TITLED: "NEWCELX ANNOUNCES STRATEGIC COLLABORATION WITH ELEDON PHARMACEUTICALS (NASDAQ: ELDN) TO ADVANCE NCEL-101 PROGRAM FOR TYPE 1 DIABETES."
EX-99.1 to Form 6-K
Feb 12, 2026, 7:13 AM ET
PRESS RELEASE TITLED: "NEWCELX REPORTS PEER-REVIEWED PUBLICATION SUPPORTING MAZINDOL IR/SR AND ADVANCES CVR MONETIZATION STRATEGY"
EX-99.1 to Form 6-K
Jan 29, 2026, 7:13 AM ET
PRESS RELEASE TITLED: "NEWCELX ANNOUNCES UPDATED CORPORATE PRESENTATION AHEAD OF KEY SPRING 2026 INVESTOR AND PARTNERING CONFERENCES"
EX-99.1 to Form 6-K
Jan 29, 2026, 7:13 AM ET
JANUARY 2026 ( NASDAQ : NCEL ) ©2026 N EW C EL X L TD . REGENERATIVE MEDICINE TO CURE TYPE 1 DIABETES 72:$5'$&85()257<3( ',$%(7(6
EX-99.2 to Form 6-K
Jan 12, 2026, 7:12 AM ET
PRESS RELEASE TITLED: "NEWCELX ANNOUNCE POSITIVE RESULTS FROM INTERNATIONAL COLLABORATIVE STUDY EXPLORING ADVANCED BIOMATERIAL
EX-99.1 to Form 6-K
Jan 5, 2026, 7:20 AM ET
PRESS RELEASE TITLED: "NEWCELX APPOINTS DR. JULIEN BOISDRON, A SWISS BIG PHARMA LEADER IN DIABETES INNOVATION, TO ITS SCIENTIFIC ADVISORY BOARD"
EX-99.1 to Form 6-K
Dec 11, 2025, 9:22 AM ET
PRESS RELEASE TITLED: "NEWCELX EXPANDS INTELLECTUAL PROPERTY FOOTPRINT WITH PUBLICATION OF DOXA PATENT APPLICATION IN CHINA"
EX-99.1 to Form 6-K
Nov 17, 2025, 7:06 AM ET
PRESS RELEASE TITLED: "NEWCELX STRENGTHENS SCIENTIFIC ADVISORY BOARD WITH APPOINTMENT OF JEREMY SHEFNER, MD, PHD, CHIEF MEDICAL OFFICER AT THE BARROW NEUROLOGICAL INSTITUTE"
EX-99.1 to Form 6-K
Nov 4, 2025, 7:15 AM ET
PRESS RELEASE TITLED: "NEWCELX CEO ISSUES LETTER TO SHAREHOLDERS"
EX-99.1 to Form 6-K
Nov 3, 2025, 8:47 AM ET
PRESS RELEASE TITLED: "NEWCELX PROVIDES BUSINESS AND STRATEGIC ROADMAP UPDATE FOLLOWING CLOSING OF MERGER WITH NLS PHARMACEUTICS LTD."
EX-99.1 to Form 6-K
Nov 3, 2025, 8:47 AM ET
INNOVATIVE THERAPIES TRANSFORMING LIVES N OVEMBER 2025 ( NASDAQ : NCEL ) ©2025 NewCelX Ltd.
EX-99.2 to Form 6-K
Oct 30, 2025, 4:17 PM ET
PRESS RELEASE TITLED: "NLS PHARMACEUTICS LTD. AND KADIMASTEM LTD. ANNOUNCE COMPLETION OF MERGER"
EX-99.1 to Form 6-K
Oct 30, 2025, 7:15 AM ET
PRESS RELEASE TITLED: "NLS PHARMACEUTICS EXPANDS CNS PIPELINE WITH AEX-6XX SERIES DEVELOPED BY AEXON LABS"
EX-99.1 to Form 6-K
Oct 29, 2025, 7:30 AM ET
PRESS RELEASE TITLED: "NLS PHARMACEUTICS AND KADIMASTEM HIGHLIGHT CONTINUED BIRD FOUNDATION SUPPORT FOR ITOL-102 DIABETES PROGRAM FOLLOWING MERGER"
EX-99.1 to Form 6-K
Oct 28, 2025, 9:21 PM ET
AMENDED AND RESTATED ARTICLES OF ASSOCIATION
EX-99.1 to Form 6-K
Oct 28, 2025, 9:21 PM ET
PRESS RELEASE TITLED: "NLS PHARMACEUTICS LTD. ANNOUNCES 1-FOR-10 REVERSE SHARE SPLIT AND NAME CHANGE IN CONNECTION WITH PROPOSED MERGER WITH KADIMASTEM."
EX-99.2 to Form 6-K
Oct 28, 2025, 4:37 PM ET
PRESS RELEASE TITLED: "NLS PHARMACEUTICS AND KADIMASTEM ANNOUNCE COMPLETION OF MATERIAL CONDITIONS PRECEDENT FOR MERGER TRANSACTION AND DELISTING DATE OF KADIMASTEM'S SHARES"
EX-99.1 to Form 6-K
Oct 27, 2025, 7:17 AM ET
PRESS RELEASE TITLED: "NLS PHARMACEUTICS AND KADIMASTEM ANNOUNCE STRATEGIC COLLABORATION BETWEEN KADIMASTEM AND TARGETGENE TO ADVANCE NEXT-GENERATION GENE-EDITED CELL THERAPIES."
EX-99.1 to Form 6-K
Oct 23, 2025, 6:04 AM ET
PRESS RELEASE TITLED: "NLS AND KADIMASTEM ANNOUNCE RECEIPT OF NASDAQ APPROVAL; MERGER EXPECTED TO CLOSE ON OCTOBER 30, 2025."
EX-99.1 to Form 6-K
Oct 9, 2025, 8:44 PM ET
UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS OF KADIMASTEM LTD. AS OF JUNE 30, 2025 AND DECEMBER 31, 2024 AND FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024
EX-99.1 to Form 6-K
Oct 9, 2025, 8:44 PM ET
AUDITED FINANCIAL STATEMENTS OF KADIMASTEM LTD. AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023
EX-99.2 to Form 6-K
Oct 9, 2025, 8:44 PM ET
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS OF NLS PHARMACEUTICS LTD. FOR THE SIX MONTHS ENDED JUNE 30, 2025
EX-99.3 to Form 6-K
Oct 3, 2025, 9:16 PM ET
UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS
EX-99.1 to Form 6-K
Oct 3, 2025, 9:16 PM ET
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF NLS PHARMACEUTICS LTD FOR THE SIX MONTHS ENDED JUNE 30, 2025
EX-99.2 to Form 6-K
Sep 30, 2025, 7:15 AM ET
PRESS RELEASE TITLED: "NLS PHARMACEUTICS SHAREHOLDERS APPROVE MERGER WITH KADIMASTEM AND RELATED PROPOSALS AT EXTRAORDINARY GENERAL MEETING."
EX-99.1 to Form 6-K
Sep 10, 2025, 6:15 AM ET
PRESS RELEASE TITLED: "KADIMASTEM AND NLS PHARMACEUTICS ANNOUNCE EFFECTIVENESS OF SEC REGISTRATION STATEMENT IN CONNECTION WITH PROPOSED MERGER."
EX-99.1 to Form 6-K
Sep 4, 2025, 8:37 AM ET
PRESS RELEASE TITLED: "NLS PHARMACEUTICS AND KADIMASTEM ANNOUNCE A HONG KONG PATENT COVERING CELL-SELECTION AND ENRICHMENT TECHNOLOGY FOR ISLETRX FOR DIABETES PATIENTS."
EX-99.1 to Form 6-K